The levonorgestrel-releasing intrauterine system: an updated review of the contraceptive and noncontraceptive uses

Camaryn E. Chrisman, Chrisman C, Camaryn Chrisman, Ribeiro P, PRICILLA RIBEIRO, Dalton VK, Vanessa K. Dalton
Clinical Obstetrics and Gynecology · 2007 · vol. 50(4) , pp. 886–897 · doi:10.1097/grf.0b013e318159c0d9 · PMID:17982331 · W2021122450
Review OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-09 ⓘ

This review covers the safety and effectiveness of the levonorgestrel-releasing intrauterine system for contraception, menstrual disturbances, and treatment of various gynecological conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The levonorgestrel containing intrauterine system is an effective and safe form of long-term yet reversible birth control. Intrauterine contraception use in the United States fell dramatically after early studies reported an association between intrauterine contraception use and later tubal infertility. Subsequent evaluation suggests that these early studies were biased. Users often experience menstrual disturbances. Informing patients of these common side effects is important to improve compliance. In addition to its contraceptive effect, the levonorgestrel intrauterine system offers potential therapeutic benefits in other clinical contexts, including menorrhagia, symptomatic fibroids, endometriosis, and endometrial suppression.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Intrauterine Devices, Medicated Intrauterine Devices, Medicated Cost-Benefit Analysis Cost-Benefit Analysis Endometriosis Endometriosis Endometriosis Female Female Female Urogenital Diseases Female Urogenital Diseases Female Urogenital Diseases Female Urogenital Diseases Humans Humans Infertility, Female Infertility, Female Infertility, Female Infertility, Female Intrauterine Devices, Medicated

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (1)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:04:47.165929+00:00
License: CC0 · commercial use OK